Compare Eli Lilly And Co (LLY) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs QUALCOMM, Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while QUALCOMM, Inc. trades at $175.5 (market cap $187.95B). The key difference: Eli Lilly And Co is far larger — about 5.5× QUALCOMM, Inc.'s market cap, and QUALCOMM, Inc. pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and QUALCOMM, Inc. for 87 Days on average.
| LLY | QCOM | |
|---|---|---|
Market Cap | $1.04T | $187.95B |
Volume | 3,064,878 | 9,535,042 |
Sector | Health | Technology |
52-Week High | $1.28K | $251.10 |
52-Week Low | $799.57 | $124.07 |
Typical Hold Time | 93 Days | 87 Days |
Enterprise Value | $1.09T | $194.92B |
Dividend Yield | 0.59% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Qualcomm (QCOM) trades at $176.01, down 0.59% on the day, with a bearish technical signal and key support at $173. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains strong profitability with a 21.01% net margin and 33.75% ROE. Recent news highlights a transformative $60 billion AI partnership with Amazon, boosting sentiment despite near-term volatility.
QCOM presents a compelling risk-reward profile with a consensus price target of $204.48, implying 16% upside. Strengths include robust cash flow and diversification into AI/data centers, but risks involve execution on new initiatives and dependence on smartphone markets. Analyst consensus leans Hold, reflecting cautious optimism amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
